# Prazer Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prazer-therapeutics

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.prazertx.com/
- Total disclosed funding: $35M
- Latest round: Series B (Apr 1, 2025)
- Investors on record: 9

## About

Prazer Therapeutics Inc. is focused on developing innovative therapeutics for refractory diseases, utilizing proprietary technologies to target previously undruggable protein aggregates and inflammatory conditions, enhancing patient care. Prazer Therapeutics Inc. specializes in creating novel treatments for complex diseases through its proprietary technologies. Founded in 2019, the company operates out of Seoul, South Korea. In July 2026,?Prazer Therapeutics Inc.?raised? KRW 50 billion in pre-IPO funding led by new investor Playground Ventures, with participation from other new investor Shinhan Asset Management. Returning investors Johnson & Johnson Innovation, WOORI Venture Partners, Company K Partners, Smilegate Investment, Premier Partners, K2 Investment Partners, and other unspecified investors also participated in this round.

The founder has a history of entrepreneurship in the biotechnology sector, although specific details about previous ventures are not provided.Prazer Therapeutics specializes in the development of innovative therapeutics aimed at treating refractory diseases, focusing on drugging previously undruggable targets. The company’s core product offerings center around its proprietary SPiDEM™ technology, designed to degrade target proteins through small molecules. These small molecules target protein aggregates and inflammatory proteins, with applications in neurodegenerative and refractory inflammatory diseases. The SPiDEM™ technology is also being utilized to create therapeutics for viral diseases by targeting host factors, primarily serving patients with hard-to-treat conditions and healthcare providers, although specific geographical markets remain undisclosed.The revenue generation model of Prazer Therapeutics is based on collaborative partnerships and potential licensing agreements for its SPiDEM™ technology and related therapeutics. The company engages in business-to-business transactions with pharmaceutical companies and research institutions, deriving revenue from milestone payments, royalties, and research collaborations that fund ongoing development efforts. Specific financial figures and pricing plans have not been disclosed, but the company’s strategic focus on therapeutic advancements positions it to leverage the growing demand for effective treatments in the healthcare market.

The company will use the July 2026 funding to advance its proprietary platform, pursue clinical trials for its core pipelines, and invest in the development of Degrader Antibody Conjugate (DAC) payload for its targeted protein degradation drugs.

## Funding rounds

- Series B, Apr 1, 2025, $20M — Johnson & Johnson Innovation, Smilegate Investment, Company K Partners, Premier Partners, QUAD Investment Management, Kiwoom Investment, K2 Investment Partners, STIC Ventures, Mirae Asset Capital
- Series A, Mar 8, 2021, $15M — Smilegate Investment, Company K Partners, Kiwoom Investment

## Investors

- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A, Series B
- Company K Partners (https://capitalatlas.ai/funds/company-k-partners) — Series A, Series B
- Kiwoom Investment (https://capitalatlas.ai/funds/kiwoom-investment) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series B
- QUAD Investment Management (https://capitalatlas.ai/funds/quad-investment-management) — Series B
- K2 Investment Partners (https://capitalatlas.ai/funds/k2-investment-partners) — Series B
- STIC Ventures (https://capitalatlas.ai/funds/stic-ventures) — Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series B